News

Orion recalls Devisol Salmiakki dietary supplement from consumers

Devisol_Salmiakki_20mikrog_200tabl Devisol_Salmiakki_20mikrog_200tabl Devisol_Salmiakki_20mikrog_230tabl Devisol_Salmiakki_20mikrog_230tablORION CORPORATION                PRESS RELEASE                 5 SEPTEMBER 2022 AT 8.00 EEST         Orion recalls Devisol Salmiakki dietary supplement from consumers…

2 years ago

Press Release: Evolution of the Board of Directors

Evolution of the Board of Directors Paris, September 5, 2022. The Board of Directors of Sanofi met on September 2,…

2 years ago

Bone Therapeutics to host Extraordinary General Meeting on 05 October 2022

REGULATED INFORMATION As a result of a technical error in the publication dated August 26, 2022, the Board of Directors…

2 years ago

POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial

Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. HansenINDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) --…

2 years ago

Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022

Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not…

2 years ago

Over 480 Million People Estimated to Have COPD, World’s Third Deadliest Disease, ResMed Study Reports

New prevalence figure 22–126% higher than previous estimatesPrevalence expected to reach 592 million by 2050Researchers urge global action on smoking…

2 years ago

Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in Funding

Leuven, BELGIUM, Boston, MA, US – September 2, 2022 – CET 10:30PM – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical…

2 years ago

DBV Technologies to Present at Upcoming Investor Conferences

Montrouge, France, September 2, 2022 DBV Technologies to Present at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345…

2 years ago

PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery

SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site Infections and Mortality In an FDA…

2 years ago

Nanomix Announces Agreement with Mobility Health to Co-Develop a Lab Development Test for Evaluating Levels of COVID-19 Circulating Antibodies

Point-of-care technology to offer patients a timely, highly accurate status of their protection against COVID-19SAN LEANDRO, Calif., Sept. 02, 2022…

2 years ago